Arlington Trust’s Biogen BIIB Stock Holding History

Arlington Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7	Closed	-$1.81K	–	532
2023 Q4	$1.81K	Buy	+7	New	+$1.72K	﹤0.01%	649

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arlington Trust's BIIB Position: Q1 2024 in Review

Arlington Trust sold out of Biogen (BIIB) in Q1 2024, closing a stake of 7 shares — an estimated $1.81K sold.

Arlington Trust first reported a position in BIIB in Q4 2023 and held it in 1 quarter. The position peaked at $1.81K in Q4 2023. 954 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

Arlington Trust reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
Arlington Trust sold 7 Biogen shares in Q1 2024, an estimated $1.81K.
Arlington Trust first reported a position in Biogen in Q4 2023 and held it in 1 quarter.
Arlington Trust's Biogen position peaked at $1.81K in Q4 2023.
954 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Arlington Trust's 13F filing for Q1 2024, filed 16 Apr 2024.